Viva Biotech Holdings

1873

KYG9390W1015

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
0.56 ^HKD	0.00%		+34.94%	-46.67%

Mar. 28	Viva Biotech Holdings Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 18	Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director	CI

Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director

January 18, 2024 at 05:22 am EST

Viva Biotech Holdings at its extraordinary general meeting held on January 18, 2024, the board announced that Mr. WANG Stephen Hui ("Mr. Wang") was appointed as a non-executive Director with effect from January 18, 2024. He will hold office for a term of three years.

Latest news about Viva Biotech Holdings

Viva Biotech Holdings Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director	Jan. 18	CI
VIVA Biotech Redeems $280 Million Convertible Bonds Ahead of 2025 Maturity	Jan. 03	MT
VIVA Biotech Sells 2.3% Stake in Viva Biotech (Shanghai)	Dec. 27	MT
VIVA Biotech Disposes of Minority Stake in Subsidiary for $15 Million	Dec. 18	MT
Viva Biotech Holdings Announces Executive Changes	Dec. 01	CI
Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer	Dec. 01	CI
Viva Biotech Buys Back $143.4 Million Convertible Bonds	Nov. 28	MT
Viva Biotech Buys Back $56.3 Million of Convertible Bonds Due 2025	Nov. 21	MT
Viva Biotech Disposes 24% Stake in Subsidiary	Nov. 20	MT
True Light Investments P Pte. Ltd., Daxue Investments Pte. Ltd., HLC VGC Fund IV L.P. and Qingdao Hongyi Investment Partnership Enterprise (Limited Partnership) completed the acquisition of an unknown minority stake in Viva Biotech Ltd. from Viva Biotech Holdings.	Nov. 19	CI
Viva Biotech Completes Post-Issue Regulatory Filing for Convertible Bonds	23-10-26	MT
Viva Biotech Buys Back $43 Million of 1% Convertible Bonds	23-10-13	MT
Viva Biotech Holdings commences an Equity Buyback Plan for 193,503,680 shares, representing 10% of its issued share capital, under the authorization approved on June 30, 2023.	23-09-28	CI
Viva Biotech Logs 64% Jump in H1 Profit	23-08-30	MT
Viva Biotech Holdings Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Viva Biotech to Swing to H1 Profit	23-08-18	MT
Viva Biotech Holdings to Sell 24% of Subsidiary for 1.06 Billion Yuan	23-08-09	MT
Viva Biotech Raises HK$470 Million from Convertible Bonds	23-07-10	MT
Viva Biotech Holdings announced that it has received HKD 470 million in funding	23-07-06	CI
Viva Biotech to Potentially Raise HK$11.7 Million through Share Issue to Individual Affiliates	23-06-12	MT
Viva Biotech Issues HK$470 Million in Convertible Bonds; Shares Fall 12%	23-06-12	MT
Temasek-backed firms buy stake in VIVA Biotech unit ahead of listing	23-06-11	RE
True Light Investments P Pte. Ltd., Daxue Investments Pte. Ltd., HLC VGC Fund IV L.P. and Qingdao Hongyi Investment Partnership Enterprise (Limited Partnership) entered into an agreement to acquire an unknown minority stake in Viva Biotech Ltd. from Viva Biotech Holdings for CNY 514.6 million.	23-06-10	CI
Viva Biotech Holdings announced that it expects to receive HKD 470 million in funding	23-06-09	CI

Chart Viva Biotech Holdings

Duration

Period

More charts

Company Profile

VIVA Biotech Holdings is a China-based investment holding company. The Company is principally engaged in the provision of the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. The Companyâs core technologies include structure-based drug discovery (SBDD) platform, fragment-based drug discovery (FBDD) platform, affinity selection mass spectrometry (ASMS) screening platform and membrane protein targeted drug discovery platform. The Company operates its businesses mainly in the United States, China, Europe and other regions.

Sector

Pharmaceuticals

Calendar

2024-06-25 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VIVA BIOTECH HOLDINGS	-46.67%	153M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals